Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) rose 0.7% during mid-day trading on Wednesday . The stock traded as high as $1.61 and last traded at $1.51. Approximately 35,889 shares traded hands during trading, a decline of 96% from the average daily volume of 905,819 shares. The stock had previously closed at $1.50.
Salarius Pharmaceuticals Stock Down 3.9 %
The company has a fifty day simple moving average of $2.14 and a two-hundred day simple moving average of $3.39. The company has a market cap of $889,530.00, a price-to-earnings ratio of -0.07 and a beta of 0.95.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($2.37) EPS for the quarter, beating the consensus estimate of ($53.60) by $51.23. On average, research analysts predict that Salarius Pharmaceuticals, Inc. will post -214.4 EPS for the current year.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Read More
- Five stocks we like better than Salarius Pharmaceuticals
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Pros And Cons Of Monthly Dividend Stocks
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- The How and Why of Investing in Gold Stocks
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
